Guobang Pharmaceuticals: Wholly-owned subsidiary obtained approval letter for Oxytetracycline veterinary drug product registration number.

Guobang Pharmaceutical announced that its wholly-owned subsidiary Zhejiang Guobang has recently received the approval document for the veterinary drug product approval number of "Tylosin" issued by the Ministry of Agriculture and Rural Affairs, with a validity period until April 20, 2031. Tylosin can be used to treat and prevent respiratory diseases in cattle and pigs, and Zhejiang Guobang has met the conditions for listing and selling. Currently, the global production of Tylosin active pharmaceutical ingredients is mainly carried out in China. The product has already passed the US FDA and EU GMP certification stages, completed registration in over 30 countries, and is expected to become a billion-dollar blockbuster. Obtaining domestic approval documents will facilitate the development of the domestic market, but product sales are subject to uncertainties such as policies and market factors.